Altimmune, Inc. announced Impairment loss on intangible asset of $12.4 million was recognized during the three months ended December 31, 2023 related to the acquired In-Process Research and Development asset associated with HepTcell. The overall response in the Phase 2 trial was deemed to be insufficient to warrant further advancement. As a result, any further development related to HepTcell has been stopped.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.285 USD | +0.90% | -1.22% | -35.38% |
05-09 | Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.38% | 512M | |
+4.78% | 109B | |
+10.63% | 105B | |
-0.38% | 22.25B | |
-12.26% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.11% | 16.85B | |
+4.61% | 13.76B | |
+34.83% | 12.46B |
- Stock Market
- Equities
- ALT Stock
- News Altimmune, Inc.
- Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023